Pharmaceuticals, Biotechnology and Life Sciences
Novartis said Tuesday its Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous treatments.
The FDA has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer.
Seattle Genetics’ results from the phase 2 of trial testing tisotumab vedotin to treat patients with relapsed or progressed metastatic cervical cancer, showed clinically meaningful and durable objective responses with a manageable safety profile.
Research includes a potential new drug for colorectal cancer, as well as new studies on geriatric oncology and supportive care medicine.
Analyses from KEYTRUDA Plus LENVIMA Trials to be Presented at 2020 ASCO Annual Meeting KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.–(BUSINESS…
RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy for treating all stages of cancer, today announced a clinical collaboration with Merck.
Coalition ignites strategic insights sooner to accelerate patient access BASKING RIDGE, N.J. & MORRISVILLE, N.C.–(BUSINESS WIRE)–Daiichi Sankyo, Inc. (hereafter, Daiichi…
Takeda’s Alunbrig long-Term results from the phase 3 ALTA 1L trial established Alunbrig as a superior first-line treatment compared to crizotinib for people with ALK+ metastatic NSCLC, including those with brain metastases.
– Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall – – Approval…